Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603168'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -26.89 Med: 1.34 Max: 28.88
Current: -26.89
During the past 13 years, Zhejiang Shapuaisi Pharmaceutical Co's highest Return-on-Tangible-Equity was 28.88%. The lowest was -26.89%. And the median was 1.34%.
SHSE:603168's Return-on-Tangible-Equity is ranked worse than 87.13% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.89
vs SHSE:603168: -26.89
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Zhejiang Shapuaisi Pharmaceutical Co Return-on-Tangible-Equity Related Terms
Zhejiang Shapuaisi Pharmaceutical Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shapuaisi Pharmaceutical Co Return-on-Tangible-Equity Chart
SHSE:603168 vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Shapuaisi Pharmaceutical Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -10.79% mean?
Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) has a Return-on-Tangible-Equity of -10.79% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors. According to the industry distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #785 out of 901 companies in the Drug Manufacturers industry, placing it in the top 87.1%.
Is Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity too high?
Zhejiang Shapuaisi Pharmaceutical Co's current Return-on-Tangible-Equity is -10.79%. Based on the distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #785 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Shapuaisi Pharmaceutical Co has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shapuaisi Pharmaceutical Co's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Shapuaisi Pharmaceutical Co ranks #785 out of 901 companies for Return-on-Tangible-Equity. This places Zhejiang Shapuaisi Pharmaceutical Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.89. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.89, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Zhejiang Shapuaisi Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Shapuaisi Pharmaceutical Co's current Return-on-Tangible-Equity is -10.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shapuaisi Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥8.99, compared to a current price of ¥5.20 — trading 42.2% below its estimated fair value. The current Return-on-Tangible-Equity is -10.79%. Zhejiang Shapuaisi Pharmaceutical Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168), the current Return-on-Tangible-Equity is -10.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shapuaisi Pharmaceutical Co (SHSE:603168) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shapuaisi Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥5.20 is trading 42.2% below its estimated GF Value™ of ¥8.99.
GuruFocus considers Zhejiang Shapuaisi Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:603168:
Return-on-Tangible-Equity: -10.79%
GF Value™: ¥8.99 vs. price of ¥5.20 (42.2% below fair value)
No single metric tells the full story. See the SHSE:603168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shapuaisi Pharmaceutical Co Ltd is a China based pharmaceutical company. It is engaged in drug research and development, production and operation. The product portfolio of the company includes oral solutions, eye drops, tablets, hard capsules, suppositories, granules, raw materials dosage forms such as medicines, rinsing agent and mixture, and others. The company operates pharmaceutical manufacturing companies, pharmaceutical sales company, pharmaceutical retail company and pharmaceutical research institute. The products offered by the company are sold in China and are also exported to the other countries.
39GF Score
Get the complete analysis for SHSE:603168
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603168 has been successfully added to your 
